Dysbiosis and Disease: Understanding the Microbial Imbalance
February 11, 2020 by Flore Clinical Editorial
Dysbiosis — the disruption of the normal commensal microbial community — is implicated in the pathogenesis of conditions ranging from inflammatory bowel disease to major depressive disorder. Understanding what constitutes dysbiosis, how it is measured, and how it is addressed is essential clinical knowledge for practitioners working at the intersection of functional and evidence-based medicine.
Defining Dysbiosis
Dysbiosis is not a single state but a spectrum of microbial disruptions that can include: loss of keystone species (e.g., Faecalibacterium prausnitzii, Akkermansia muciniphila), expansion of pathobionts (e.g., Bilophila wadsworthia, Enterobacteriaceae), reduced taxonomic diversity, and altered functional capacity (reduced butyrate production, increased LPS translocation).
Disease Associations
| Condition | Key Microbial Findings |
|---|---|
| Crohn's Disease | ↓ F. prausnitzii, ↑ E. coli (AIEC) |
| Type 2 Diabetes | ↓ butyrate producers, ↑ opportunistic pathogens |
| Major Depression | ↓ Lactobacillus, ↓ Bifidobacterium, ↑ LPS producers |
| Obesity | ↑ Firmicutes:Bacteroidetes ratio, ↓ Akkermansia |
| C. diff infection | Loss of colonization resistance, ↓ diversity |
Pathogenic Mechanisms
The mechanisms linking dysbiosis to systemic disease are increasingly well-characterized. Reduced butyrate production impairs colonocyte energy supply and weakens tight junctions, increasing intestinal permeability (see our article on leaky gut syndrome). Elevated lipopolysaccharide (LPS) from gram-negative bacteria triggers systemic low-grade inflammation via TLR-4 activation — a mechanism proposed in metabolic endotoxemia by Cani et al. (Diabetes, 2007).
Clinical Approach to Dysbiosis
Precision microbiome analysis identifies which species are depleted or overgrown, enabling targeted rather than empirical probiotic therapy. Read more in our overview of precision probiotics and microbiome fundamentals.